35Pharma

Executive Summary

35Pharma is a private, preclinical-stage biotechnology company headquartered in the United States, focused on discovering and developing small molecule therapeutics for inflammatory and autoimmune diseases. Founded in 2020, the company leverages its expertise in immunology and small molecule chemistry to address unmet medical needs in conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. With a team of 50-200 employees, 35Pharma is advancing a pipeline of novel oral drugs designed to modulate key immune pathways while improving safety and tolerability compared to existing biologics. Despite being in early stages, the company's approach has the potential to offer convenient, cost-effective alternatives for patients suffering from chronic autoimmune disorders. The company has not yet disclosed its lead programs or financial details, but preclinical studies are expected to demonstrate proof-of-concept in relevant animal models. 35Pharma's differentiation lies in its proprietary small molecule platform, which could enable oral administration and reduced immunogenicity. As it moves toward Investigational New Drug (IND)-enabling studies, the company is likely seeking partnerships or additional financing to support clinical development. The preclinical stage presents significant risk, but if successful, 35Pharma's oral therapies could capture substantial market share in the multibillion-dollar autoimmune space. Key upcoming milestones include the nomination of a development candidate, initiation of IND-enabling toxicology studies, and eventual IND filing.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate nomination for autoimmune indication70% success
• Q2 2027Initiation of IND-enabling toxicology studies60% success
• Q1 2028IND filing for first-in-human trial50% success